Urology in focus: Key moments from 2025

Click the image or this link to access this content

How to engage with the content:

• Open the publication by clicking the image or link above. It will open the interactive publication in a new browser window.
• Arrows on both sides of the screen allow you to navigate from page to page.
• There are buttons on the bottom-right of your screen to display thumbnails of all the pages beneath the viewer, or to zoom in/out, or make full screen.
• When you come across video content, you can click to watch within the publication.
• For now, the link performs better for desktop/laptop viewing. You can view on mobile but some interactive experiences may not be available.
• Questions? Problems? Feedback? Please reach out to Assistant Managing Editor Ben Saylor.

What's in the publication:

• Testosterone and CV risk: We spoke with several experts on the significance of the FDA's class-wide labeling changes for testosterone products.
• Biden's prostate cancer diagnosis underscores importance of screening, awareness: Biden's diagnosis of grade group 5 de novo metastatic hormone-sensitive prostate cancer has offered a sobering reminder that prostate cancer remains a growing concern for public health.
• FDA approves durvalumab/chemo for muscle-invasive bladder cancer: "This is another tool in our armamentarium to treat muscle-invasive bladder cancer and represents an advance compared to where we've been over the past few decades," says Matthew D. Galsky, MD.
• Genitourinary syndrome of menopause guideline released: In an interview with Urology Times®, Karyn S. Eilber, MD, describes the significance of the new document.
• FDA approves mitomycin intravesical solution for recurrent LG-IR-NMIBC: Rahul Mehan, MD, and Nick Liu, MD, discuss the FDA approval of mitomycin in a 5-part Special Report: RX Review series.